Patents Assigned to Johannes Gutenberg-Universitat Mainz
-
Patent number: 11919951Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: February 7, 2022Date of Patent: March 5, 2024Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11920194Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.Type: GrantFiled: June 1, 2018Date of Patent: March 5, 2024Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Ugur Sahin, Martin Suchan, Barbara Schrörs, Martin Löwer, Petra Oehm
-
Patent number: 11858988Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.Type: GrantFiled: July 7, 2020Date of Patent: January 2, 2024Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universität MainzInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
-
Patent number: 11859008Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.Type: GrantFiled: December 30, 2020Date of Patent: January 2, 2024Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universität MainzInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
-
Patent number: 11789621Abstract: Summarizing the invention, a computer-implemented method is provided. The computer-implemented method comprises: allocating, by an operating system kernel, a physical memory block for a privileged function; storing, by the operating system kernel, the privileged function in the physical memory block; creating, by the operating system kernel, an entry for the physical memory block in a mapping table, wherein the entry associates the physical memory block to a virtual memory block in an address space of a program; setting, by the operating system kernel, a security bit for the entry in the mapping table; executing, by a processor, the program in unprivileged mode; and if the program requests the privileged function: checking, by the processor, whether the security bit is set; if the security bit is set, switching, by the processor, execution to kernel mode for performing the privileged function.Type: GrantFiled: November 27, 2020Date of Patent: October 17, 2023Assignee: JOHANNES GUTENBERG-UNIVERSITAT MAINZInventor: André Brinkmann
-
Patent number: 11732308Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.Type: GrantFiled: December 23, 2020Date of Patent: August 22, 2023Assignees: Astellas Pharma Inc., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBHInventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
-
Patent number: 11713346Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.Type: GrantFiled: May 9, 2016Date of Patent: August 1, 2023Assignees: BioNTech Cell & Gene Therapies GmbH, TRON—Translationale Onkologie An Der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
-
Patent number: 11701413Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.Type: GrantFiled: April 10, 2018Date of Patent: July 18, 2023Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Sebastian Kreiter, Christina Krienke, Jutta Petschenka, Lena Mareen Kranz, Mustafa Diken
-
Patent number: 11559587Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.Type: GrantFiled: September 23, 2019Date of Patent: January 24, 2023Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SEInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Patent number: 11504419Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.Type: GrantFiled: October 26, 2018Date of Patent: November 22, 2022Assignees: BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
-
Patent number: 11492628Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.Type: GrantFiled: October 5, 2016Date of Patent: November 8, 2022Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
-
Patent number: 11473085Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.Type: GrantFiled: February 13, 2019Date of Patent: October 18, 2022Assignees: GANYMED PHARMACEUTICALS GMBH, JOHANNES GUTENBERG-UNIVERSITAT MAINZInventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
-
Patent number: 11471522Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.Type: GrantFiled: March 21, 2018Date of Patent: October 18, 2022Assignees: BIONTECH SE, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBHInventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
-
Patent number: 11447825Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.Type: GrantFiled: August 9, 2016Date of Patent: September 20, 2022Assignee: Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Bettina Trinschek, Kazuki Satoh, Helmut Jonuleit
-
Publication number: 20220261678Abstract: The present description relates to a method and a device for providing anyons that may be used for topological quantum computation. The method comprises the steps of providing a magnetic material containing at least one magnetic texture providing a superconductor containing at least one vortex; creating at least one magnetic texture-vortex pair by coupling the magnetic material to the superconductor, wherein each magnetic texture-vortex pair binds an anyon being localized at the vortex of the respective magnetic texture-vortex pair in the superconductor.Type: ApplicationFiled: June 10, 2020Publication date: August 18, 2022Applicant: Johannes Gutenberg-Universität MainzInventors: Jonas Nothhelfer, Kjetil Magne Dørheim Hals, Karin Everschor-Sitte, Matteo Rizzi
-
Patent number: 11395852Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.Type: GrantFiled: October 11, 2018Date of Patent: July 26, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Özlem Türeci
-
Patent number: 11384076Abstract: The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.Type: GrantFiled: August 9, 2018Date of Patent: July 12, 2022Assignees: UNIVERSITÄT REGENSBURG, UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZInventors: Siavosh Mahboobi, Andreas Sellmer, Herwig Pongratz, Bernardette Pilsl, Oliver Krämer, Thomas Kindler, Mandy Beyer
-
Patent number: 11345731Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.Type: GrantFiled: June 18, 2019Date of Patent: May 31, 2022Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
-
Patent number: 11337922Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.Type: GrantFiled: May 25, 2021Date of Patent: May 24, 2022Assignees: BioN Tech SE, Tron—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz GmbHInventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer